Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
10:38pm, Sunday, 14'th Mar 2021
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
04:55am, Friday, 12'th Mar 2021
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised t
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
01:13pm, Sunday, 07'th Mar 2021
New York, New York--(Newsfile Corp. - March 7, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are ad
Galapagos' Filgotinib Shows Interim Safety In Ongoing Studies
08:12am, Thursday, 04'th Mar 2021
Galapagos NV (NASDAQ: GLPG) has announced interim results from two ongoing safety studies investigating the effect of Jyseleca (filgotinib) on sperm parameters in males with inflammatory bowel dis
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
03:20am, Wednesday, 03'rd Mar 2021
NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contac
Is Galapagos Stock a Bad-News Buy Right Now?
06:55am, Tuesday, 23'rd Feb 2021
Despite some serious setbacks, this beaten-down biotech could be a terrific bargain at recent prices.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
02:20pm, Monday, 22'nd Feb 2021
New York, New York--(Newsfile Corp. - February 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors ar
Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q4 2020 Results - Earnings Call Transcript
09:06pm, Friday, 19'th Feb 2021
Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q4 2020 Results - Earnings Call Transcript
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
01:05am, Friday, 19'th Feb 2021
NEW YORK, Feb. 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors are advised to contac
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV - GLPG
10:00pm, Monday, 15'th Feb 2021
New York, New York--(Newsfile Corp. - February 15, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Galapagos NV ("Galapagos" or the "Company") (NASDAQ: GLPG). Such investors ar
Gilead (GILD) & Galapagos Discontinue Development of IPF Drug
04:37pm, Thursday, 11'th Feb 2021
Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.
Gilead, Galapagos drug fails in Phase 3 clinical study
08:25am, Thursday, 11'th Feb 2021
Shares of Gilead Sciences Inc. were down 0.1% in premarket trading on Thursday, the day after the company said an experimental idiopathic pulmonary fibrosis drug it was developing with Galapagos faile
Gilead Sciences and Galapagos Shutter Their Pulmonary Fibrosis Program
02:52pm, Wednesday, 10'th Feb 2021
Despite solid signs of efficacy in mid-stage trials, the partners are shutting down all clinical trials with ziritaxestat.
Galapagos, Gilead Sciences Pull Plug On Ziritaxestat Clinical Trials
11:10am, Wednesday, 10'th Feb 2021
Galapagos NV (NASDAQ: GLPG) and Gilead Sciences Inc (NASDAQ: GILD) have decided to stop the ISABELA Phase 3 studies evaluating ziritaxestat in patients with idiopathic pulmonary fibrosis (IPF).
The Gilead, Galapagos Pipeline Opportunities That Are Turning Morgan Stanley Bullish
11:21am, Tuesday, 19'th Jan 2021
Gilead Sciences, Inc. (NASDAQ: GILD) and its R&D partner Galapagos ADR Representing Ord Shs (NASDAQ: GLPG) received an upgrade each from Morgan Stanley. The Gilead, Galapagos Analyst: Matthew Harrison
